Affimed Announces FDA Clearance of IND to Commence First-in-Huma

AFMD: Affimed N.V.
2019-11-07 16:01:00
Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers